Neutrophil to lymphocyte ratio and risk of neoplastic progression in patients with Barrett's esophagus

被引:10
|
作者
Peleg, Noam [1 ,2 ]
Schmilovitz-Weiss, Hemda [1 ,2 ]
Shamah, Steven [1 ,2 ]
Schwartz, Ariel [3 ]
Dotan, Iris [1 ,2 ]
Sapoznikov, Boris [1 ,2 ]
机构
[1] Rabin Med Ctr, Div Gastroenterol, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[3] Rabin Med Ctr, Dept Pathol, Petah Tiqwa, Israel
关键词
DIAGNOSIS; MANAGEMENT; CANCER; GUIDELINES; DYSPLASIA; SURVIVAL;
D O I
10.1055/a-1292-8747
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Patient's with Barrett's esophagus (BE) are at risk of progression to esophageal adenocarcinoma (EAC). Neutrophil to lymphocyte ratio (NLR) was found to be a predictor of poor prognosis in patients with EAC; however, its performance in premalignant esophageal lesions is vague. We aimed to evaluate the utility of NLR as a predictor of histologic progression in patients with BE. Methods A prospective cohort of patients with proven BE in a tertiary referral center was retrospectively analyzed. All biopsies were reviewed by an expert gastrointestinal pathologist. The discriminatory capacity of NLR was evaluated by area under the receiver operating characteristic (AUC) curve analysis and Cox regression analysis. Results 324 patients (mean age 62.3 years, 241 [74.4%] males) were included in the final analysis. Overall, 13 patients demonstrated histologic progression to neoplasia over a mean follow-up of 3.7 years (progression risk 1.0% per year). The AUC of NLR for progression to high grade dysplasia (HGD) or EAC was 0.88 (95% confidence interval [CI] 0.83-0.96), and baseline NLR was associated with a 3-fold increase of progression to HGD and EAC during follow-up (hazard ratio [HR] 3.2, 95%CI 1.5-5.8; P <0.001). Notably, in a subgroup analysis of patients with nondysplastic BE (NDBE) at presentation, NLR was also a risk factor for histologic progression (HR 2.4, 95%CI 1.7-3.4; P <0.001). Conclusion NLR predicted histologic progression in patients with BE. Patients with NDBE and NLR above 2.4 can be considered for specific surveillance programs with shorter intervals between sessions.
引用
收藏
页码:774 / 781
页数:8
相关论文
共 50 条
  • [21] Immunohistochemical biomarkers for risk stratification of neoplastic progression in Barrett esophagus
    Janmaat, V. T.
    van Olphen, S. H.
    Biermann, K.
    Looijenga, L.
    Bruno, M. J.
    Spaander, M. C. W.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] Risk Factors for Predicting Neoplastic Progression in Patients With Barrett's Esophagus and Low-Grade Dysplasia
    Zavos, Christos
    Verbeek, Romy E.
    Leenders, Max
    Moons, Leon M.
    Vleggaar, Frank P.
    Siersema, Peter D.
    GASTROENTEROLOGY, 2013, 144 (05) : S675 - S676
  • [23] Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: A prospective analysis
    Chao, Dennis L.
    Maley, Carlo C.
    Wu, Xifeng
    Farrow, Diana C.
    Galipeau, Patricia C.
    Sanchez, Carissa A.
    Paulson, Thomas G.
    Rabinovitch, Peter S.
    Reid, Brian J.
    Spitz, Margaret R.
    Vaughan, Thomas L.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (10) : 1935 - 1940
  • [24] Predictors for Neoplastic Progression in Patients With Barrett's Esophagus: A Prospective Cohort Study
    Sikkema, M.
    Looman, C. W. N.
    Steyerberg, E. W.
    Kerkhof, M.
    Kastelein, F.
    van Dekken, H.
    van Vuuren, A. J.
    Bode, W. A.
    van der Valk, H.
    Ouwendijk, R. J. T.
    Giard, R.
    Lesterhuis, W.
    Heinhuis, R.
    Klinkenberg, E. C.
    Meijer, G. A.
    ter Borg, F.
    Arends, J. W.
    Kolkman, J. J.
    van Baarlen, J.
    de Vries, R. A.
    Mulder, A. H.
    van Tilburg, A. J. P.
    Offerhaus, G. J. A.
    ten Kate, F. J. W.
    Kusters, J. G.
    Kuipers, E. J.
    Siersema, P. D.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (07): : 1231 - 1238
  • [25] Symptoms and Endoscopic Features at Barrett's Esophagus Diagnosis: Implications for Neoplastic Progression Risk
    Coleman, Helen G.
    Bhat, Shivaram K.
    Murray, Liam J.
    McManus, Damian T.
    O'Neill, Orla M.
    Gavin, Anna T.
    Johnston, Brian T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 (04): : 527 - 534
  • [26] The use of imaging and biomarkers in diagnosing Barrett's esophagus and predicting the risk of neoplastic progression
    Ramzan, Zeeshan
    Nassri, Ammar B.
    Huerta, Sergio
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2014, 14 (05) : 575 - 591
  • [27] Use of Proton Pump Inhibitors and Risk of Progression of Barrett's Esophagus to Neoplastic Lesions
    Islami, Farhad
    Kamangar, Farin
    Boffetta, Paolo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (10): : 2646 - 2648
  • [28] Tissue protein biomarkers of neoplastic progression in Barrett's esophagus
    Conrads, Thomas P.
    Hood, Brian L.
    Flint, Melanie S.
    Jones-Laughner, Jacqueline
    Sun, Mai
    Jobe, Blair
    Davison, Jon
    CANCER RESEARCH, 2010, 70
  • [29] Mitoses, Genomic Instability and Neoplastic Progression in Barrett's Esophagus
    Coco, D.
    Srivastava, A.
    Sanchez, C.
    Fong, P. Y.
    Li, X.
    Cowan, D.
    Maley, C.
    Blount, P.
    Reid, B.
    Odze, R. D.
    MODERN PATHOLOGY, 2011, 24 : 145A - 146A
  • [30] Mitoses, Genomic Instability and Neoplastic Progression in Barrett's Esophagus
    Coco, D.
    Srivastava, A.
    Sanchez, C.
    Fong, P. Y.
    Li, X.
    Cowan, D.
    Maley, C.
    Blount, P.
    Reid, B.
    Odze, R. D.
    LABORATORY INVESTIGATION, 2011, 91 : 145A - 146A